Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 75 mg - capsule, hard - excipient ingredients: silicon dioxide; iron oxide yellow; iron oxide red; titanium dioxide; magnesium stearate; sodium starch glycollate type a; gelatin; lactose monohydrate; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 125 mg - capsule, hard - excipient ingredients: gelatin; sodium starch glycollate type a; iron oxide yellow; silicon dioxide; magnesium stearate; titanium dioxide; iron oxide red; lactose monohydrate; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Den europeiske union - engelsk - EMA (European Medicines Agency)

pfizer europe ma eeig - dacomitinib monohydrate - carcinoma, non-small-cell lung - antineoplastic agents - vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) activating mutations.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 125 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; silicon dioxide; crospovidone; magnesium stearate; succinic acid; titanium dioxide; hypromellose; triacetin; iron oxide red; indigo carmine aluminium lake - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 100 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; silicon dioxide; crospovidone; magnesium stearate; succinic acid; titanium dioxide; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - palbociclib, quantity: 75 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; silicon dioxide; crospovidone; magnesium stearate; succinic acid; titanium dioxide; hypromellose; triacetin; iron oxide red; indigo carmine aluminium lake - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.

Nigeria - engelsk - NAFDAC (National Agency for Food and Drugs Administration and Control)

recombinant human epidermal growth factor

Nigeria - engelsk - NAFDAC (National Agency for Food and Drugs Administration and Control)

recombinant human epidermal growth factor 60ug

Canada - engelsk - Health Canada

project clean inc - octyl decyl dimethyl ammonium chloride; dioctyl dimethyl ammonium chloride; didecyl dimethyl ammonium chloride; benzalkonium chloride - solution - 1.627%; 0.814%; 0.814%; 2.17% - octyl decyl dimethyl ammonium chloride 1.627%; dioctyl dimethyl ammonium chloride 0.814%; didecyl dimethyl ammonium chloride 0.814%; benzalkonium chloride 2.17% - disinfectants (for agents used on object)

Canada - engelsk - Health Canada

project clean inc - octyl decyl dimethyl ammonium chloride; dioctyl dimethyl ammonium chloride; didecyl dimethyl ammonium chloride; benzalkonium chloride - solution - 1.627%; 0.814%; 0.814%; 2.17% - octyl decyl dimethyl ammonium chloride 1.627%; dioctyl dimethyl ammonium chloride 0.814%; didecyl dimethyl ammonium chloride 0.814%; benzalkonium chloride 2.17% - disinfectants (for agents used on object)